London, UK, 22 June 2022: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, is pleased to announce an update on its business and operations following the Company’s Admission to AIM on 28 March 2022. Highlights Successfully completed sixth harvest from its Phase 1 grow …
Listen to the podcaste on Spotify Here is a great short podcast with Celadon Pharmaceuticals Plc CEO James Short explaining how pharma-grade cannabis-based medicines might help the 8 million adults with untreatable chronic pain in the UK, and why the UK is uniquely placed to build a burgeoning industry. Fresh off becoming the only AIM-listed cannabinoid …
Celadon Pharmaceuticals Plc is proud to be featured in The Guardian newspaper today with a story titled “Inside one of the first licenced medical cannabis labs in Britain“. Click here to read the full story.
There has been an excellent article published in The Times today about the groundbreaking 5,000 patient trial by one of our subsidiary companies LVL Health Medical Cannabis Clinic to study the use of medicinal cannabis to treat chronic pain. Celadon Pharmaceuticals Plc is getting ready to become the provider of medical-grade cannabis for the trial …
Celadon this week begins life as a listed company; the first company to be admitted to the London Stock Exchange AIM Market since the legalisation of cannabis-based medicinal products in 2018, and the first since GW Pharma. Governed by the UK regulators and trials underway targeting MHRA approval, we have ambitious plans to advance the …
Meet our CEO, Jim Short, as he talks to Christine Corrado from Proactive Investors about Celadon Pharmaceuticals Plc, what we do and our ambitious plans for the company. Click here to see the full Proactive Investors article.
Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m. Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and …
Input your search keywords and press Enter.